Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Unveils Action Plan to Boost Biosimilars

  • Post author:Sam
  • Post published:July 18, 2018
  • Post category:Drug Industry Daily

FDA Commissioner Scott Gottlieb announced the release of a new action plan for biosimilars on Wednesday and said it would help prime the “anemic” biosimilar market. Source: Drug Industry Daily

Continue ReadingFDA Unveils Action Plan to Boost Biosimilars

Baxter Facility Warned for Serious Production Failures, Poor Conditions

  • Post author:Sam
  • Post published:July 17, 2018
  • Post category:Drug Industry Daily

Baxter subsidiary Claris Injectables was hit with a warning letter for significant water damage, falsely recording data and neglecting to properly investigate out-of-specification results at its Ahmedabad, Gujarat facility. Source:…

Continue ReadingBaxter Facility Warned for Serious Production Failures, Poor Conditions

Drugmakers Take Aim At Pharmacy Benefits Manager

  • Post author:Sam
  • Post published:July 17, 2018
  • Post category:Drug Industry Daily

Fees for pharmacy benefit managers should no longer be calculated based on a medicine’s list price, the nation’s largest drug manufacturers’ association says in new comments filed with federal regulators.…

Continue ReadingDrugmakers Take Aim At Pharmacy Benefits Manager

House Passes Legislation for OTC Monograph Program Reform

  • Post author:Sam
  • Post published:July 17, 2018
  • Post category:Drug Industry Daily

The U.S. House of Representatives passed the Over-the-Counter Monograph Safety, Innovation and Reform Act, a bill that would reform the OTC monograph system by using a user fee system to…

Continue ReadingHouse Passes Legislation for OTC Monograph Program Reform

FDA May Extend NDA Pathway to Increase Access to Nonprescription Drugs

  • Post author:Sam
  • Post published:July 17, 2018
  • Post category:Drug Industry Daily

The FDA proposes to extend the new drug application pathway to include therapeutic indications that have not previously been available for nonprescription drugs, Commissioner Scott Gottlieb said on Tuesday in…

Continue ReadingFDA May Extend NDA Pathway to Increase Access to Nonprescription Drugs

FDA Takes Kansas City Manufacturer to Task Over Serious Sanitation Violations

  • Post author:Sam
  • Post published:July 16, 2018
  • Post category:Drug Industry Daily

The FDA cited Q A Laboratories after a lengthy inspection of its of Kansas City, Missouri facility revealed serious sanitation deficiencies and other nonconformances. Source: Drug Industry Daily

Continue ReadingFDA Takes Kansas City Manufacturer to Task Over Serious Sanitation Violations

EMA Publishes First Update on Its Clinical Data Open Access Policy

  • Post author:Sam
  • Post published:July 16, 2018
  • Post category:Drug Industry Daily

The European Medicines Agency issued the first report on its open access policy for clinical data submitted by sponsors in their marketing applications for new drugs. Source: Drug Industry Daily

Continue ReadingEMA Publishes First Update on Its Clinical Data Open Access Policy

Pfizer’s Hospira Facility in India Hit With Lengthy 483

  • Post author:Sam
  • Post published:July 16, 2018
  • Post category:Drug Industry Daily

The FDA cited Pfizer’s Hospira manufacturing facility in Sriperumbudur, Tamil Nadu for a slew of repeat deficiencies, including falsifying data, in a Form 483 flagged as Official Action Indicated –…

Continue ReadingPfizer’s Hospira Facility in India Hit With Lengthy 483

Indivior Wins Injunction Against Dr. Reddy’s Suboxone Generic

  • Post author:Sam
  • Post published:July 16, 2018
  • Post category:Drug Industry Daily

A federal court issued a preliminary injunction against Dr. Reddy’s generics for Indivior’s addiction treatment Suboxone (buprenorphine and naloxone) pending the outcome of a patent challenge. Source: Drug Industry Daily

Continue ReadingIndivior Wins Injunction Against Dr. Reddy’s Suboxone Generic

Senate Report Calls for Stronger DEA Control Over Opioid Distribution

  • Post author:Sam
  • Post published:July 13, 2018
  • Post category:Drug Industry Daily

In her third report on opioid abuse in the U.S., Sen. Claire McCaskill (D-Mo.) recommends giving the DEA more authority to penalize pharmaceutical distributors for failing to meet reporting obligations,…

Continue ReadingSenate Report Calls for Stronger DEA Control Over Opioid Distribution
  • Go to the previous page
  • 1
  • …
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.